Results are awaited from clinical trials evaluating the safety and efficacy of combining IL-21 with other immunotherapeutic agents (IL-21/Anti programmed cell death 1 [PD-1] against solid tumors/NCT01629758, IL-21/ipilimumab against melanoma, NCT01489059). The gene discussed is IL21; the disease is melanoma.